Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1700034

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Trastuzumab Deruxtecan
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make a comparative assessment of the adequacy of the reasons the (a) National Institute for Health and Care Excellence has been unable and (b) Scottish Medicines Consortium has been able to recommend Enhertu for use on the NHS.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	20959
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) makes authoritative, evidence-based recommendations for the National Health Service in England on whether new licensed medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. Decisions on the availability of medicines in Scotland are a matter for the devolved administration.</p><p>The NICE published guidance in 2021 and 2023 recommending Enhertu, also known as trastuzumab deruxtecan, for the treatment of NHS patients with HER2-positive breast cancer through the Cancer Drugs Fund, and it is now available to eligible NHS patients in England in line with the NICE’s recommendations.</p><p>The NICE is currently evaluating Enhertu for the treatment of metastatic HER2-low breast cancer, and has not yet published final guidance. Stakeholders have had an opportunity to appeal against the NICE’s draft recommendations, and the NICE will consider any appeals through the established process and publish final guidance in due course.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 15:01:22 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3930 label Biography information for Caroline Lucas

1700068

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Trastuzumab Deruxtecan
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether NICE is taking steps to make Enhertu available to the National Health Service to treat incurable HER2-low secondary breast cancer.
	tabling member constituency	South Holland and The Deepings
	tabling member printed	Sir John Hayes
	uin	20865
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing guidance for the National Health Service on whether Enhertu can be recommended for routine NHS funding, based on an assessment of the costs and benefits. The NICE was unfortunately unable to recommend Enhertu as a clinically and cost-effective use of NHS resources in its final draft guidance published on 5 March 2024. Stakeholders have had an opportunity to appeal against the NICE’s draft recommendations, and the NICE will consider any appeals through the established process, and will publish final guidance in due course.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 15:03:45 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	350 label Biography information for Sir John Hayes

1700249

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Sodium Valproate: Compensation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what her planned timetable is for publishing a response to the Hughes Report on compensation for patients damaged by sodium valproate, published 7 February 2024.
	tabling member constituency	Ellesmere Port and Neston
	tabling member printed	Justin Madders
	uin	21105
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The Government commissioned the Patient Safety Commissioner (PSC) to produce a report on redress for those affected by sodium valproate and pelvic mesh. We are grateful to the PSC and her team for completing this report, and our sympathies remain with those affected by sodium valproate and pelvic mesh. The Government is now carefully considering the PSC’s recommendations, and will respond substantively in due course.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 16/04/2024 13:36:40 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4418 label Biography information for Justin Madders

1700334

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether her Department has made a recent assessment of the potential merits of using breast density assessment software at women's first breast cancer screening appointments; and if she will make an assessment of the potential impact of that technology on women's awareness of their personal risk of developing breast cancer.
	tabling member constituency	North Warwickshire
	tabling member printed	Craig Tracey
	uin	21156
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The Breast Screening Risk Adaptive Imaging for Density trial is looking into the use of supplementary imaging techniques for women, within the standard breast screening programme, who are found to have radiographically dense breast tissue. The UK National Screening Committee, which advises ministers and the National Health Service in all four countries in the United Kingdom, will review this evidence when it becomes available.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 10:56:31 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4509 label Biography information for Craig Tracey

1700510

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make it her policy to allow pharmacies to sell vitamin B12 injections.
	tabling member constituency	Loughborough
	tabling member printed	Jane Hunt
	uin	21397
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>To make a medicinal product available for sale in a pharmacy without a prescription, the product must be reclassified to pharmacy only status, also known as [P] medicines, by the Medicines and Healthcare products Regulatory Agency (MHRA).</p><p>This process is triggered by an application submitted to the MHRA by a company which holds a licence for the particular product. The MHRA will consider all submitted applications, with a decision to reclassify a medicine reached following a robust evaluation of the relevant data, including evidence of the safe use and supply of the product without a prescription. The company must also demonstrate in their application that the criteria specified in relevant legislation, such as the Human Medicines Regulations 2012, have been met.</p><p>In accordance with the Human Medicines Regulations 2012, regulation 62(3), Prescription-Only Medicine status will apply where: a direct or indirect danger exists to human health, even when used correctly, if used without medical supervision; there is frequently incorrect use, which could lead to direct or indirect danger to human health; further investigation of the activity or side-effects is required; or the product is normally prescribed for parenteral administration, via injection.</p><p>Currently, United Kingdom law specifies that all products administered by injection must be subject to a prescription. The MHRA is therefore unable to reclassify the status of injections, including Vitamin B12, to [P] medicines, as this would not be consistent with the legislation.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 11:03:29 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4839 label Biography information for Jane Hunt

1700548

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Mental Health Services: Wellingborough
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to support the recruitment and retention of mental health specialists in Wellingborough constituency.
	tabling member constituency	Wellingborough
	tabling member printed	Gen Kitchen
	uin	21433
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>To deliver the NHS Long Term Plan’s mental health commitments and help reduce waiting times in the Wellingborough constituency and nationwide, our aim has been to grow the mental health workforce nationally by an additional 27,000 professionals by March 2024.</p><p> </p><p>We are making positive progress, delivering three quarters of this, or approximately 20,800 new professionals, by December 2023, with further growth expected to have been achieved once the full year figures for 2023/24 are available. This growth is in addition to the commitment to grow the National Health Service’s mental health workforce by 19,000 between 2016/17 and 2020/21, as set out in Stepping Forward to 2020/21: the mental health workforce plan for England, which was achieved in September 2021.</p><p> </p><p>At a national level, we are committed to attracting, training, and recruiting the mental health workforce of the future, as well as retaining and developing our current workforce. The NHS Long Term Workforce Plan’s modelling projections set out a need to grow the overall mental health and learning disability workforce the fastest of all care settings, at 4.4% per year up to 2036/37, to help improve access to services and quality of care.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 16/04/2024 10:53:27 answering member 4492 label Biography information for Maria Caulfield
	tabling member	5011 label Biography information for Gen Kitchen

1700570

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Neurodiversity: Women
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will commission research into the impact of (a) autism and (b) ADHD on women.
	tabling member constituency	Lewisham West and Penge
	tabling member printed	Ellie Reeves
	uin	21455
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The Department commissions research through the National Institute for Health and Care Research (NIHR). The NIHR is currently funding research to address measurement bias in the assessment of the presentation of autism in women, and to develop a new psychometric tool assessing the female-dominant phenotype of autism. The NIHR previously funded a study to improve the accuracy and efficiency of autism assessment for adults which, while not specific to women, will be relevant to their experiences of receiving a diagnosis. The NIHR has also funded research into topics that impact autistic individuals differently, for example how to adapt suicide safety plans to address self-harm, suicidal ideation, and suicide behaviours in autistic adults.</p><p>The NIHR welcomes funding applications for research into any aspect of human health, including the impact of autism and attention deficit hyperactivity disorder on women. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. In all disease areas, the amount of NIHR funding depends on the volume and quality of scientific activity.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 11:36:36 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4620 label Biography information for Ellie Reeves

1700571

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Neurodiversity: Women
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will commission research into the impact of hormonal changes on neurodiverse women throughout their lives.
	tabling member constituency	Lewisham West and Penge
	tabling member printed	Ellie Reeves
	uin	21456
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The Department commissions research through the National Institute for Health and Care Research (NIHR). The NIHR is not currently funding any specific research into the impact of hormonal changes on neurodiverse women, but welcomes funding applications for research into any aspect of human health. Applications are subject to peer review and judged in open competition, with awards being made based on the importance of the topic to patients and health and care services, value for money, and scientific quality.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 11:14:48 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4620 label Biography information for Ellie Reeves

1700572

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Autism: Premenstrual Dysphoric Disorder
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will commission research into the reasons for which autistic women are more likely to suffer from premenstrual dysphoric disorder throughout their lives.
	tabling member constituency	Lewisham West and Penge
	tabling member printed	Ellie Reeves
	uin	21457
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The Department commissions research through the National Institute for Health and Care Research (NIHR). The NIHR is not currently funding any specific research to understand the reasons why autistic women are more likely to suffer from premenstrual dysphoric disorder, but welcomes funding applications for research into any aspect of human health. Applications are subject to peer review and judged in open competition, with awards being made based on the importance of the topic to patients and health and care services, value for money, and scientific quality.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 11:17:41 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4620 label Biography information for Ellie Reeves

1699274

	registered interest
	date	27/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Physician Associates
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government, further to the Written Answer by Lord Markham on 25 March (HL2978), why they have specified how physician associates (PAs) are to be used, specifically with undifferentiated patients, rather than allowing GP practices to make their own decisions about the use of PAs.
	tabling member printed	Baroness Bennett of Manor Castle
	uin	HL3652
	answer	answer is ministerial correction date of answer 05/04/2024 answer text <p>Physician Associates (PAs) work within a defined scope of practice and limits of competence. NHS England has provided recent guidance on the use of PAs in general practice (GP) teams. As set out in the Network Contract Directed Enhanced Service, PAs should be adequately supervised by a GP when providing care for undifferentiated patients.</p><p>In terms of employment choices, GPs are self-employed contractors to the National Health Service, and it is largely up to employers to determine how best to staff their primary care network or GP, to best meet the needs of their population.</p> answering member printed Lord Markham question first answered 05/04/2024 13:32:33 answering member 4948 label Biography information for Lord Markham
	tabling member	4719 label Biography information for Baroness Bennett of Manor Castle